Free tool
Heavily traded stocks
We cover 34 companies whose typical session turns over more than $10.00M. The median market value in the group is $2.95B. Across the group, the median move over the past trading day is 0.00%. 94% of the 34 with a 200-day average trade above it. Price change over the past year runs from −25.4% to +273.8% across the middle 80 percent of the group, with a median of +53.3%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
34 of 7,336 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% |
| RHC.AX | Ramsay Health Care Limited | $8.27B | Mid cap | +50.11% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +143.24% |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | +93.71% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.84% |
| ANN.AX | Ansell Limited | $4.17B | Mid cap | +18.41% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| OGN | Organon & Co. | $3.62B | Mid cap | +50.67% |
| PLSE | Pulse Biosciences, Inc. | $3.43B | Mid cap | +203.47% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.30B | Mid cap | +281.97% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% |
| AMBU-B.CO | Ambu A/S | $2.69B | Mid cap | −19.13% |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% |
| BAVA.CO | Bavarian Nordic A/S | $2.51B | Mid cap | −7.97% |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% |
| ONT.L | Oxford Nanopore Technologies plc | $2.41B | Mid cap | −2.24% |
| EKTA-B.ST | Elekta AB (publ) | $2.20B | Mid cap | +26.10% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| PRGO | Perrigo Company plc | $2.05B | Mid cap | −36.05% |
| 366A.T | WELLNESS COMMUNICATIONS CORPORA | $89.79M | Micro cap | −23.84% |
| 4512.T | Wakamoto Pharmaceutical Co.,Ltd. | $67.16M | Micro cap | +1.97% |
| 4584.T | Kidswell Bio Corporation | $55.44M | Micro cap | −26.03% |
| 4583.T | Chiome Bioscience Inc. | $42.82M | Micro cap | −36.76% |
| PMI | Picard Medical, Inc. | $20.13M | Micro cap | +113.51% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.